PTI Proteostasis Therapeutics Inc.

0.66
+0.03  (+5%)
Previous Close 0.63
Open 0.65
Price To Book 0.41
Market Cap 33,821,818
Shares 51,128,976
Volume 649,104
Short Ratio
Av. Daily Volume 671,074

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2 28-day data released December 11, 2017 - showed improvements in FEV1 of 5.2%. Phase 2 28-day data released December 11, 2017 - showed improvements in FEV1 of 5.2%.
PTI-428
Cystic fibrosis
Development to be discontinued due to lack of efficacy - March 25, 2019.
PTI-801 + Symdeko
Cystic fibrosis
Proceed to 28 day studies to confirm efficacy.
PTI-801 and PTI-808
Cystic fibrosis
Phase 2 commencement of dosing announced July 25, 2019 with data due 1Q 2020.
PTI-428 + PTI-801 + PTI-808
Cystic fibrosis
Development to be discontinued due to lack of efficacy.
PTI-428 + Symdeko
Cystic fibrosis

Latest News

  1. Could Proteostasis Therapeutics, Inc.'s (NASDAQ:PTI) Investor Composition Influence The Stock Price?
  2. Proteostasis Therapeutics (PTI) Reports Q2 Loss, Lags Revenue Estimates
  3. Proteostasis Therapeutics Reports Second Quarter 2019 Financial Results and Provides Corporate Update
  4. Will Proteostasis Therapeutics (PTI) Report Negative Q2 Earnings? What You Should Know
  5. Proteostasis (PTI) to Post Q2 Earnings: What's in Store?
  6. Proteostasis Therapeutics Initiates Dosing in Global Phase 2 Study in Cystic Fibrosis
  7. Proteostasis Therapeutics Announces Management Changes and Appointments
  8. Is Proteostasis Therapeutics, Inc. (NASDAQ:PTI) Excessively Paying Its CEO?
  9. How Proteostasis Therapeutics, Inc. (NASDAQ:PTI) Could Add Value To Your Portfolio
  10. Proteostasis Therapeutics Receives Orphan Drug Designation in the EU for PTI-428 for the Treatment of Cystic Fibrosis
  11. Proteostasis Therapeutics Announces Presentations and Hosts Educational Symposium at the 42nd European Cystic Fibrosis Conference
  12. Vertex Selects Triple Combo Regimen for Regulatory Submission
  13. Proteostasis Therapeutics to Present at the 2019 RBC Capital Markets Global Healthcare Conference
  14. Proteostasis Therapeutics Appoints Dr. Badrul Chowdhury, Former FDA Director of Pulmonology, Allergy, and Rheumatology, to Board of Directors
  15. Proteostasis Therapeutics (PTI) Reports Q1 Loss, Tops Revenue Estimates
  16. Proteostasis: 1Q Earnings Snapshot
  17. Proteostasis Therapeutics Reports First Quarter 2019 Financial Results and Provides Corporate Update
  18. Market Sentiment Around Loss-Making Proteostasis Therapeutics, Inc. (NASDAQ:PTI)
  19. Analysts Estimate Proteostasis Therapeutics (PTI) to Report a Decline in Earnings: What to Look Out for